Search PubMed⌕ Search

Biomedical subjects

B Kubanek

Publications and source records attributed to B Kubanek.

At least 91 records · Page 5Linked to original sources
PubMed1990

[HIV study of the German Red Cross of West Germany 1985-1989: prevalence/incidence and mode of infection, retrospective studies].

All German Red Cross Blood Banks in the FRG cooperate in a study on prevalence and epidemiology of HIV-antibodies in blood donors. The prevalences of 1 to 2 Western blot positive donors per 100,000 donors/donations quarterly since 1987 are constantly low. The measures undertaken to defer persons at risk seem to be effective. The "look back" data confirm the "rest risk" of HIV-infections by blood products in the FRG which is estimated to be about 1:1 million on the basis of the epidemiologic data. More than 90% of the donors infected are members of risk groups of heterosexual partners to persons at risk. Until today, in blood donors there is no indication of an increasing number of unaware heterosexually acquired HIV-infections.

Blood Banks↗
PubMed1990

[Current data on the prevalence and epidemiology of HIV from the HIV study by the German Red Cross of West Germany].

From the multicenter study of the Red Cross Blood Banks in the FRG HIV-antibody prevalences and incidences are documented since July 1985. Constantly low prevalences and incidences since 1987 of less than 2 Western blot (Wb)-positive donors and less than 1 Wb-positive donor per 100,000 donors respectively confirm our estimate of the rest risk of an HIV-infection by blood products of 1:500,000 to 1:3 million donations. In the epidemiologic details there seems to be a trend to an increase of the incidence in male repeat blood donors. The modes of HIV-infection in blood donors have changed to an increasing number of infections acquired in heterosexual contacts to persons at risk.

AIDS Serodiagnosis↗
PubMed1989

[Blood donor selection in providing anticytomegalovirus-negative blood components].

Sera of 1731 blood donors of the Ulm blood bank were screened for cytomegalovirus (CMV) antibodies. Prevalence of these antibodies was 37%. The seroconversion rate among 1090 anti-CMV-negative blood donors was 13 per thousand per year for the whole donor population over a period of 27 months and depended on age. It was 16 per thousand per year for donors aged 18-40 years, but only 7 per thousand for those over 41 years old. Seropositivity was higher in women than men. To provide anti-CMV-negative blood requires a prescreened anti-CMV-negative donor group and the rescreening of each further donated blood component.

Adolescent↗
PubMed1989

Evaluation of remission state in chronic myeloid leukemia patients after bone marrow transplantation using cytogenetic and molecular genetic approaches.

The remission state of 13 Philadelphia positive chronic myeloid leukemia patients was studied after bone marrow transplantation (BMT) by cytogenetic and Southern blot analysis of the breakpoint cluster region (BCR) gene. Eight of 13 patients showed neither clinical nor genetic evidence of residual disease. In two patients hematological relapse was confirmed by cytogenetic and molecular analysis. Evidence for residual leukemic cells in otherwise complete remission was obtained genetically in three patients. One of the latter cases revealed BCR rearrangement despite negative cytogenetic findings, while in another patient cytogenetic relapse was observed without demonstrable rearrangement within the major BCR. Our results may indicate that cytogenetic and molecular genetic methods complement rather than replace each other for the detection of residual CML cells after BMT.

Adolescent↗
PubMed1989

Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin.

Restriction fragment length polymorphisms (RFLPs) of the X-chromosome genes hypoxanthine phosphoribosyl transferase (HPRT) and phosphoglycerate kinase (PGK) were studied in 34 female patients with primary myelodysplastic syndromes (MDS). Twelve patients (35%) were heterozygous at the HPRT or PGK loci for BamHI or BglI RFLPs, respectively. In eight patients showing PGK polymorphisms, clonality was determined by X-chromosome inactivation analysis. These included patients from different morphologic subtypes: four with refractory anemia (RA), two with RA and ring sideroblasts (RARS), one patient with RA with excess of blasts (RAEB), and one with chronic myelomonocytic leukemia (CMML). A monoclonal pattern of X-chromosome inactivation was observed in seven cases. In a further case characterized by bone marrow hypoplasia, peripheral blood (PB) leukocytes were polyclonal in origin. Following low-dose cytarabine therapy, reversion to polyclonal hematopoiesis was observed in a case of RAEB indicating the presence of residual normal hematopoietic stem cells with the capacity for marrow reconstitution. The clonal relation of lymphoid and granulocyte/monocyte lineages was studied directly in two cases of CMML exhibiting somatic mutations of N-ras or Ki-ras oncogenes. By selective oligonucleotide hybridization to ras gene sequences amplified in vitro by the polymerase chain reaction, a mutated ras allele was demonstrated in PB granulocytes, monocytes, and B and T lymphocytes of both patients. We conclude that MDS arise from a multipotent hematopoietic stem cell with the potential for myeloid and lymphoid differentiation.

Adult↗
PubMed1988

[Transfusion hepatitis. Occurrence and comparison of risks of blood transfusion and surgery].

The incidence of hepatitis (B and non-A, non-B) was determined in a prospective multicentre study of 1100 hospital patients during 12 months without or after surgery and with or without transfusion. The incidence was 3.6% (4 of 111 patients) after surgery and transfusion, and 0.5% (5 of 989) without transfusion - with or without surgery. The incidence of hepatitis B was significantly higher in the transfused group, while non-A, non-B hepatitis had the same incidence in all three groups. Hepatitis was clinically manifest in only three of the nine patients. The remaining six silent ones were uncovered by a careful prospective follow-up plan. Thus the incidence of hepatitis in this study was higher than has been reported in retrospective series. However, the absolute number of cases is small and the confidence limits thus rather wide: the incidence of non-A, non-B hepatitis must be interpreted with caution.

Adolescent↗
PubMed1988

[Autologous blood transfusion. Goals and benefits, limitations and risks demonstrated in a practical concept].

Autologous transfusion as an alternative to homologous blood is useful, but its applicability is limited to a few patients, as we have shown in the autologous program at the University Hospital of Ulm. Each concept, even more an interdisciplinary one as autologous transfusion, includes risks. Risk factors arising primarily from donation and hemodilution are determined by the patient himself. As it is impossible to evaluate these risks in advance of anesthesia and surgical procedures the program has to provide guidelines and stringent limits to guarantee safety. Should these be ignored, the risks for the patient will be even higher than the risks of homologous transfusion that provide motivation for autotransfusion.

Blood Transfusion, Autologous↗
PubMed1987

The inflammation mediators interleukin 1 and hepatocyte-stimulating factor are differently regulated in human monocytes.

Human peripheral monocytes can be induced by bacterial lipopolysaccharide to produce the inflammatory mediators interleukin 1 (IL 1) and hepatocyte-stimulating (HS) activity. IL1 and HS activities were separated by gel permeation chromatography. It is also shown that the two monokines are differently regulated. Evidence for this stems from the finding that monocytes cultured for 24 h lose their ability to produce IL1 in response to lipopolysaccharide, while synthesis of HS activity remains essentially unaffected.

Dose-Response Relationship, Drug↗
PubMed1987

Coagulation factor XIII A and B subunits in bone marrow and liver transplantation.

The polymorphism of the coagulation factor XIIIA and B subunits was determined before and after bone marrow or liver transplantation. It could be shown that the FXIIIA phenotype of the recipient was replaced by donor phenotype after bone marrow transplantation, whereas the phenotype of FXIIIB remained of recipient origin. In contrast, the FXIIIB phenotype changed to donor type after orthotopic liver transplantation but not the FXIIIA phenotype. The results indicate that the FXIIIA protein is produced in hemopoiesis, most likely in megakaryocytes and FXIIIB protein in the liver. Depending on the site of synthesis, FXIII alleles can be used as a marker in engraftment of FXIIIA-incompatible bone marrow transplantation or as a marker in FXIIIB-incompatible orthotopic liver transplantation.

Alleles↗
PubMed1987

Comparison of three different methods used in the preparation of leukocyte-poor platelet concentrates.

We compared three methods for preparing leukocyte-poor platelet concentrates from random donors: the centrifugation procedure 400 g/6 min, the filtration by Immugard TFIG 500 Y and the Cutter Leukotrap platelet pooling system. The most efficient method with regard to removal of leukocytes and platelet yield could be obtained by filtration through the Immugard filter. Platelet loss was less than 10% and the residual leukocyte count was lower than 10 X 10(6).

Blood Platelets↗
PubMed1987

[Collection of thrombocyte concentrates and coagulation active fresh plasma with the Haemonetics PCS system].

More intensive chemotherapeutic regimens in patients with leukemia or malignant disease lead to an increasing demand for platelet concentrates. As conventional preparation of platelets from fresh whole blood is limited by the number of blood donors, new methods have to be investigated. Plasmapheresis with simultaneous collection of platelets is favored. We tested the new Haemonetics PCS system (Haemonetics Corp., Braintree, Mass.). Beside the effectivity of the measure, we were interested in the quality of the products. The simultaneous collection of hemostatic active plasma and platelet concentrates did not produce the same quality as our routine products.

Adult↗
PubMed1986

Bone-marrow transplantation for immunodeficiencies and osteopetrosis: European survey, 1968-1985.

In this retrospective analysis of allogeneic bone-marrow transplantation (BMT) carried out between 1969 and 1985 at fourteen European centres in 162 patients with sixteen different types of inherited immunodeficiencies and osteopetrosis, the overall survival with functional grafts was 51.7% (85 patients), with a minimum follow-up of 5 months. In patients with severe combined immunodeficiency HLA-matched (n = 41) and T-cell-depleted HLA-mismatched BMT (n = 46) resulted in 68% and 57% disease-free survival, respectively; after HLA-mismatched transplants, older age (greater than 6 months) and adenosine-deaminase deficiency resulted in poorer survival. Eight other lethal immunodeficiencies, including profound T-cell deficiencies, Wiskott-Aldrich syndrome, Kostmann syndrome, LFA-1/CR 3/p150,95 deficiency, and Chediak-Higashi syndrome as well as malignant osteopetrosis, have been successfully treated by BMT. In this group, survival with functional graft was 47% with HLA-matched and 29% with T-cell-depleted HLA-mismatched BMT. Engraftment failure was the major complication in this group. Poorer prognosis was associated with older patients, profound T-cell deficiencies, and the degree of HLA incompatibility.

Adolescent↗